OncoMatch/Clinical Trials/NCT06289062
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Is NCT06289062 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Cisplatin for cervical cancer.
Treatment: Camrelizumab · Cisplatin · Nab paclitaxel — This multicenter, prospective clinical trial is designed to enroll PD-L1 expression-positive patients with stage IB1 cervical cancer who desire fertility preservation to undergo neoadjuvant chemotherapy in combination with a PD-1 inhibitor to evaluate the rate of complete pathologic remission, treatment-related adverse events, pregnancy rate, miscarriage rate, preterm birth rate, live birth rate, EFS and OS.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) overexpression (CPS ≥1)
Positive PD-L1 expression by preoperative pathology, i.e., Combined Positive Score (CPS) ≥1
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including but not limited to other anti-PD-1 and anti-PD-L1 antibodies
Cannot have received: chemotherapy
receipt of chemotherapy
Cannot have received: radiation therapy
receipt of...pelvic radiation
Cannot have received: allogeneic bone marrow or solid organ transplant
Patients who have received a previous allogeneic bone marrow or solid organ transplant
Lab requirements
Blood counts
white blood cell (wbc) ≥3.5×10^9/l, neutrophil (neu) ≥1.5×10^9/l, platelet (plt) ≥100×10^9/l
Kidney function
blood urea nitrogen (bun) and cr ≤normal
Liver function
serum bilirubin ≤1.5 times the upper limit of normal, aminotransferase ≤1.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06289062 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 overexpression is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 45 years or younger.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages